February 14–16, 2015

Tenth International Symposium on Regional Cancer Therapies
Sheraton Sand Key Resort
Clearwater Beach, Florida

Sponsored by
David C. Koch
Regional Cancer Therapy Center and
University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences and
UPMC Cancer Centers

In Collaboration with
The University of Maryland Marlene and Stewart Greenebaum Cancer Center
The Medical College of Wisconsin Cancer Center

Course Co-Directors
H. Richard Alexander, MD
Professor of Surgery
University of Maryland School of Medicine
Baltimore, Maryland

David L. Bartlett, MD
Professor of Surgery
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

Robert P. Edwards, MD
Professor, Obstetrics, Gynecology and Reproductive Sciences
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania

T. Clark Gamblin, MD, MS
Associate Professor of Surgery
Medical College of Wisconsin
Milwaukee, Wisconsin

For additional information or to register online, contact:
https://ccehs.upmc.com

UPMC CancerCenter
Partner with University of Pittsburgh Cancer Institute

David C. Koch Regional Cancer Therapy Center
UPMC Cancer Pavilion, Suite 4135
150 Centre Avenue
Pittsburgh, PA 15232

Nonprofit Org.
U.S. Postage
PAID
Pittsburgh, PA
Permit No. 3834
INTENT AND OVERVIEW

This course is designed to cover the most recent advances in cancer therapy that are primarily of a regional focus, such as gastrointestinal, intraperitoneal, hepatic, ovarian and thoracic. Upon completion of the activity, learners from several disciplines should be able to discuss the latest regional therapies in surgical oncology.

WHO SHOULD ATTEND

This course is designed for physicians and nurses practicing in the areas of Medical, Surgical, Thoracic and Gynecologic Oncology and Gastroenterology.

CONTINUING EDUCATION CREDIT

The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Pittsburgh School of Medicine designates this live activity for a maximum of 20.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Other health care professionals are awarded 2.0 continuing education units (CEU’s) which are equal to 20.0 contact hours.

SPECIAL NEEDS

Participation by all individuals is encouraged. Advance notification of any special needs will help us provide better service. Please notify us of your needs at least two weeks in advance of the program by calling Maureen Hewko at (412) 623-5993.

Interactive Audio Response System being used!

SCHEDULE – SATURDAY, FEBRUARY 14, 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30 am</td>
<td>Registration and Breakfast</td>
</tr>
<tr>
<td>6:45 am</td>
<td>Welcome</td>
</tr>
<tr>
<td>7:00 am</td>
<td>Moderators: Steven Ahrendt, MD, and Konstantinos Votanopoulos, MD</td>
</tr>
<tr>
<td>7:00 am</td>
<td>The Role of Ki-67 and Preoperative Clinical Parameters to Select</td>
</tr>
<tr>
<td></td>
<td>Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients to Cytoreduction and HIPEC</td>
</tr>
<tr>
<td></td>
<td>Shigeki Kusamura, MD, et. al.</td>
</tr>
<tr>
<td>7:15 am</td>
<td>Clinicopathologic Characteristics and Prognostic Predictors of Survival</td>
</tr>
<tr>
<td></td>
<td>in Patients With Signet Ring or Adenocarcinoma of the Appendix</td>
</tr>
<tr>
<td></td>
<td>Treated with Cytoreductive Surgery and HIPEC</td>
</tr>
<tr>
<td></td>
<td>Chukwuemeka Ihemelandu, MD, et. al.</td>
</tr>
<tr>
<td>7:30 am</td>
<td>Biologic Factors Associated with Survival in Patients with Pseudomyxoma Peritonei</td>
</tr>
<tr>
<td></td>
<td>Sean Judge, MD, et. al.</td>
</tr>
<tr>
<td>7:45 am</td>
<td>Diagnostic Laparoscopy is a Safe and Effective Screening Tool for HIPEC</td>
</tr>
<tr>
<td></td>
<td>Rebecca Marmor, MD, et. al.</td>
</tr>
<tr>
<td>8:00 am</td>
<td>Desmoplastic Small Round Cell Tumor: Are all Patients Stage 4?</td>
</tr>
<tr>
<td></td>
<td>Andrea Hayes-Jordan, MD, et. al.</td>
</tr>
<tr>
<td>8:15 am</td>
<td>Outcomes of HIPEC and Cytoreductive Surgery in Young Patients with Peritoneal Carcinomatosis</td>
</tr>
<tr>
<td></td>
<td>Mashaal Dhir, MD, et. al.</td>
</tr>
<tr>
<td>8:30 am</td>
<td>A Prognostic Model for Predicting Overall Survival in Patients with Peritoneal Carcinomatosis of an Appendiceal Origin Treated with Cytoreductive Surgery and HIPEC</td>
</tr>
<tr>
<td></td>
<td>Chukwuemeka Ihemelandu, MD, et. al.</td>
</tr>
<tr>
<td>8:45 am</td>
<td>Knowledge, Attitudes, and Practice of HIPEC Surgeons Regarding Nutrition Support</td>
</tr>
<tr>
<td></td>
<td>George Salti, MD, et. al.</td>
</tr>
<tr>
<td>9:00 am</td>
<td>Impact of Major Complications on Patients’ Quality of Life After</td>
</tr>
<tr>
<td></td>
<td>Cytoreductive Surgery and HIPEC</td>
</tr>
<tr>
<td></td>
<td>Trevor Hamilton, MD, et. al.</td>
</tr>
</tbody>
</table>

We Gratefully Acknowledge Support from:
The Shadyside Hospital Foundation
and
Magee-Womens Research Institute & Foundation
9:15 am  **DEBATE:**
HIPEC is an Accepted Approach for Sarcomatosis
**PRO:** Lana Bijelic, MD — **CON:** Kiran Turaga, MD

9:45 am  Break

**Moderators: Robert Edwards, MD, and Marcello Deraco, MD**

10:15 am  **Risk Stratification and Selection of Patients for Cytoreductive Surgery and HIPEC According to Risk of Procedure Related Mortality**
Shigeki Kusamura, MD, et. al.

10:30 am  **Age-Related Morbidity and Mortality with Cytoreductive Surgery and Intraperitoneal Chemotherapy: An ACS NSQIP Database Review**
Madalyn Peters, MD, et. al.

10:45 am  **Stoma Creation and Reversal after Cytoreductive Surgery with HIPEC**
Andrea Doud, MD, et. al.

11:00 am  **The American Society of Peritoneal Surface Malignancies (ASPSM) Multi-Institution Evaluation of 773 Patients with Epithelial Ovarian Cancer with Peritoneal Metastases**
Jesus Esquivel, MD, et. al.

11:15 am  **Systemic Hyperthermia Delivered as Hyperthermic Extracorporeal Applied Tumor Therapy (HEATT), for Recurrent Ovarian Cancer: Case Report of Safe Delivery of Six Cycles**
Roger Vertrees, PhD, et. al.

11:30 am  **HIPEC Outcomes in Ovarian Epithelial Cancer at Index Surgery, Salvage and Palliative CRS/HIPEC**
Duncan Watley, MD, et. al.

11:45 am  **Cytoreductive Surgery with HIPEC is a Therapeutic Option for Patients with Uterine Leiomyosarcoma after Hysterectomy and Morcellation**
Lana Bijelic, MD, et. al.

Noon  **GUEST LECTURER**
Novel Intraperitoneal Immunotherapy Approaches to Ovarian Cancer
Ronald Alvarez, MD

12:30 pm  Break for Lunch

12:45 pm  **CONTROVERSIAL CASE DISCUSSIONS**
**Moderator:** H. Richard Alexander, MD
**Case Discussants:** Edward Levine, MD, Daniel Labow, MD, and John Kane III, MD, Jesus Esquivel, MD, and Brian Loggie, MD

- **Rapid Recurrence of Low-Grade Mucinous Appendiceal Neoplasm — Chemotherapy or Reoperation or Observation?**
- **Completely Resected Ruptured Mucinous Appendiceal Neoplasm (Low-Grade) — Observation or Reoperation?**
- **High-Volume Colorectal Cancer with Good Response to Chemotherapy, but Persistent High PCI — Is CRS/HIPEC Ever an Option?**
- **Low-Volume, High-Grade Peritoneal Mesothelioma — Chemotherapy or Cytoreductive Surgery Plus HIPEC?**

1:30 pm  **Saturday Session Adjournment**

6:00 pm  **Poster Sessions**

7:00 pm  **MEET THE PROFESSOR RECEPTION**
Presentation of Gabriella Graham Patient Advocate Award

**Schedule — Sunday, February 15, 2015**

6:30 am  **Registration and Breakfast**

6:45 am  **Welcome**

**Moderators: T. Clark Gamblin, MD, MS, and James Pingpank Jr., MD**

7:00 am  **Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Intrahepatic Cholangiocarcinoma**
Thejus Jayakrishnan, MD, et. al.

7:15 am  **Long Term Follow-up of Isolated Hepatic Perfusion for Uveal Melanoma Liver Metastases**
Roger Olsson Bagge, MD, et. al.

7:30 am  **Safety and Efficacy of Transarterial Chemoembolization in Patients with Transjugular Intrahepatic Portosystemic Shunts**
John Miura, MD, et. al.
<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:45 am</td>
<td>A Single Institutions Experience with Percutaneous Hepatic Perfusion for Unresectable Melanoma or Sarcoma to the Liver</td>
<td>Omar Rashid, MD, et. al.</td>
</tr>
<tr>
<td>8:00 am</td>
<td>TACE for Metastatic NET with Massive Hepatic Tumor Burden: Is the Benefit Worth The Risk?</td>
<td>Mio Kitano, MD, et. al.</td>
</tr>
<tr>
<td>8:15 am</td>
<td>Treatment of Metastatic Neuroendocrine Tumors (NET) with Transarterial Chemoembolization Using Doxorubicin-Eluting Beads (DEBDOX)</td>
<td>Mura Assifi, MD, et. al.</td>
</tr>
<tr>
<td>8:30 am</td>
<td>GUEST LECTURER Update on Liver-Directed Therapies for Hepatic Malignancy</td>
<td>Michael Soulen, MD</td>
</tr>
<tr>
<td>9:00 am</td>
<td>Break/Exhibitors/Posters</td>
<td></td>
</tr>
<tr>
<td>9:00 am</td>
<td><strong>Moderators: Douglas Tyler, MD, and Jonathan Zager, MD</strong></td>
<td></td>
</tr>
<tr>
<td>9:30 am</td>
<td>Overall Survival (OS) Analysis from a Randomized Phase 3 Trial of Talimogene Laherparepvec (T-VEC) versus Subcutaneous Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Patients with Unresectable Regional Melanoma Metastases</td>
<td>Howard Kaufman, MD, et. al.</td>
</tr>
<tr>
<td>9:45 am</td>
<td>Induction of Anti-Melanoma Immunity After Intralesional Ablative Therapy</td>
<td>Amod A. Sarnaik, MD, et. al.</td>
</tr>
<tr>
<td>10:00 am</td>
<td>3D CT for Accurate Isolated Regional Therapy Limb Volume Calculation</td>
<td>Rebecca Tuttle, MD, et. al.</td>
</tr>
<tr>
<td>10:15 am</td>
<td>Lymph Node Ratio is an Important Prognostic Factor in Melanoma</td>
<td>Alessandro Testori, MD, et. al.</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Systemic Anti-Tumor Effects Associated with Ipilimumab Preconditioning and Isolated Limb Perfusion</td>
<td>Minhyung Kim, MD, et. al.</td>
</tr>
<tr>
<td>10:45 am</td>
<td>Melphalan ILI Can Produce an Abscopal Effect in the Presence of Systemic Checkpoint Blockade</td>
<td>Masahito Tsutsui, MD, et. al.</td>
</tr>
<tr>
<td>11:00 am</td>
<td>Exploring Doxorubicin as a Mediator of Immunogenic Cell Death in a Regional Chemotherapy Immune Competent Murine Model of Advanced Extremity Melanoma</td>
<td>Masahito Tsutsui, MD, et. al.</td>
</tr>
<tr>
<td>11:15 am</td>
<td>Break/Exhibitors/Posters</td>
<td></td>
</tr>
<tr>
<td>11:30 am</td>
<td>The Learning Curve of Cytoreductive Surgery and HIPEC: Analysis of 324 Procedures in a Tertiary Center</td>
<td>Wencesluo Vasquez-Jimenez, MD, et. al.</td>
</tr>
<tr>
<td>11:45 am</td>
<td>Perioperative Outcomes after HIPEC for Gastric Peritoneal Carcinomatosis</td>
<td>Audrey Choi, MD, et. al.</td>
</tr>
<tr>
<td>Noon</td>
<td>Extreme Cytoreductive Surgery and HIPEC: Outcomes from a Single Tertiary Institution</td>
<td>Yaniv Berger, MD, et. al.</td>
</tr>
<tr>
<td>12:15 pm</td>
<td>Mexican National Effort to Integrate Cytoreductive Surgery and HIPEC into the Management of Gastrointestinal and Gynecologic Cancer</td>
<td>Guillermo Flores Ayala, MD, et. al.</td>
</tr>
<tr>
<td>12:30 pm</td>
<td>GUEST LECTURER Theoretical Considerations for an Optimal CRS and HIPEC</td>
<td>Paul Sugarbaker, MD</td>
</tr>
<tr>
<td>1:00 pm</td>
<td>Break for Lunch</td>
<td></td>
</tr>
<tr>
<td>1:15 pm</td>
<td>Best of PSOGI, International Congress on Peritoneal Surface Malignancies</td>
<td>David L. Bartlett, MD</td>
</tr>
<tr>
<td>1:45 pm</td>
<td>Sunday Session Adjournment</td>
<td></td>
</tr>
<tr>
<td>6:00 pm</td>
<td>Poster Viewing</td>
<td></td>
</tr>
<tr>
<td>7:00 pm</td>
<td>ASPSM Meeting</td>
<td></td>
</tr>
<tr>
<td>7:00 pm</td>
<td><strong>Poster Viewing</strong></td>
<td></td>
</tr>
<tr>
<td>7:00 pm</td>
<td><strong>ASPSM Meeting</strong></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speakers</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>6:30 am</td>
<td>Registration and Breakfast</td>
<td></td>
</tr>
<tr>
<td>6:45 am</td>
<td>Welcome</td>
<td>Moderators: Haroon Choudry, MD and Joseph Skitzki, MD</td>
</tr>
<tr>
<td>7:00 am</td>
<td>Clinical Outcome, Genomic Profile Analysis and Possible Therapeutic</td>
<td>Jesus Esquivel, MD, et. al.</td>
</tr>
<tr>
<td></td>
<td>Options in 11 Patients with Mucinous Appendiceal Neoplasms Treated with</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cytoreductive Surgery and HIPEC</td>
<td></td>
</tr>
<tr>
<td>7:15 am</td>
<td>Radiovirotherapy of Colorectal Peritoneal Carcinomatosis Using a</td>
<td>J. Andrea McCart, MD, et. al.</td>
</tr>
<tr>
<td></td>
<td>Somatostatin Receptor-Expressing Oncolytic Virus Combined with 177-Lu-DOTATOC</td>
<td></td>
</tr>
<tr>
<td>7:30 am</td>
<td>Proposal for a Renewed Cancer Index (PCI) and Completeness of Cytoreduction</td>
<td>Paolo Sammartino, MD, et. al.</td>
</tr>
<tr>
<td></td>
<td>(CC) Scores Evaluation Based on Tridimensional Integrated Sharable Digital</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tool</td>
<td></td>
</tr>
<tr>
<td>7:45 am</td>
<td>Malignant Peritoneal Mesothelioma: Characterization of Inflammatory</td>
<td>Sean Judge, MD, et. al.</td>
</tr>
<tr>
<td></td>
<td>Response within the Peritoneal Microenvironment</td>
<td></td>
</tr>
<tr>
<td>8:00 am</td>
<td>HIPEC and IP Treatment in Peritoneal Malignancies</td>
<td>Gleneara Bates, MD, et. al.</td>
</tr>
<tr>
<td>8:15 am</td>
<td>Early Identification of DPAM in “At Risk” MAN Patients — A New Approach</td>
<td>Jason Foster, MD, et. al.</td>
</tr>
<tr>
<td></td>
<td>to MAN Surveillance</td>
<td></td>
</tr>
<tr>
<td>8:30 am</td>
<td>Impact of Restricted Fluid Administration During Cytoreductive Surgery</td>
<td>James Padussis, MD, et. al.</td>
</tr>
<tr>
<td></td>
<td>and Hyperthermic Intraperitoneal Chemoperfusion on Perioperative Outcomes</td>
<td></td>
</tr>
<tr>
<td>8:45 am</td>
<td>Conditional Survival as a Patient Centered Metric for Patients with</td>
<td>Kiran Turaga, MD, et. al.</td>
</tr>
<tr>
<td></td>
<td>Appendiceal Adenocarcinoma</td>
<td></td>
</tr>
<tr>
<td>9:00 am</td>
<td>GUEST LECTURER</td>
<td>D. Scott Merrell, PhD</td>
</tr>
<tr>
<td></td>
<td>A Core Microbiome Associated with the Peritoneal Tumors of PMP</td>
<td></td>
</tr>
<tr>
<td>9:30 am</td>
<td>Break/Exhibitors/Posters</td>
<td>Moderators: James Cusack, MD, and Garrett Nash, MD</td>
</tr>
<tr>
<td>10:00 am</td>
<td>Promoting Entry into Clinical Trials and Improving Access to Specialist</td>
<td>Mary Hessdorffer, NP</td>
</tr>
<tr>
<td></td>
<td>Treatment and Care</td>
<td></td>
</tr>
<tr>
<td>10:15 am</td>
<td>Effects of HIPEC on Peritoneal Metastases Developed from Gastric Cancer</td>
<td>Yutaka Yonemura, MD, et. al.</td>
</tr>
<tr>
<td>10:30 am</td>
<td>Matched Case-Control Study of HIPEC for the Prevention and Early Treatment</td>
<td>Dario Baratti, MD, et. al.</td>
</tr>
<tr>
<td></td>
<td>of Colorectal Cancer Peritoneal Metastases</td>
<td></td>
</tr>
<tr>
<td>10:45 am</td>
<td>Adjuvant HIPEC for Patients with High-Risk Peritoneal-Based Malignancies</td>
<td>Jeffrey Sussman, MD, et. al.</td>
</tr>
<tr>
<td></td>
<td>Who Benefits and How Much?</td>
<td></td>
</tr>
<tr>
<td>11:00 am</td>
<td>Conditional Survival After Cytoreductive Surgery with HIPEC for Low and</td>
<td>Harveshp Mogal, MD, et. al.</td>
</tr>
<tr>
<td></td>
<td>High Grade Appendiceal Primaries</td>
<td></td>
</tr>
<tr>
<td>11:15 am</td>
<td>Malignant Peritoneal Mesothelioma: Incorporation of a Novel Pathologic</td>
<td>Dario Baratti, MD, et. al.</td>
</tr>
<tr>
<td></td>
<td>Grading into a Recently Proposed tnM Classification Improves Outcome</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Prediction</td>
<td></td>
</tr>
<tr>
<td>11:30 am</td>
<td>Cytoreductive Surgery and HIPEC in Patients with Liver Involvement</td>
<td>Yaniv Berger, MD, et. al.</td>
</tr>
<tr>
<td>11:45 am</td>
<td>Safety and Efficacy of Concurrent Surgical Therapy for Peritoneal</td>
<td>Stephanie Downs-Canner, MD, et. al.</td>
</tr>
<tr>
<td></td>
<td>Carcinomatosis and Synchronous Hepatic Metastases in Patients with</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Disseminated Colorectal Cancer</td>
<td></td>
</tr>
</tbody>
</table>
INTERESTING CASE PRESENTATIONS

Moderator: Charles Staley, MD

Cytoreductive Surgery and HIPEC for Fibrolamellar Hepatocellular Carcinoma with Carcinomatosis
Nathan Hinkle, MD, et. al.

Pseudomyxoma Peritonei from a Borderline Mucinous Tumor Arising in an Ovarian Mature Cystic Teratoma
Amareshwar Chiruvella, et. al.

Recurrence of Peritoneal Mesothelioma (originally epitheliod) as a Rapidly Enlarging Mass of Malignant Mesothelioma
Michael D. Kluger, MD

Complete Pathologic Response Found at the Time of CRS and HIPEC for PC from Rectal Cancer
Rajesh Nair, MD

Gastric Cancer Carcinomatosis
Joseph Kim, MD

Desmoplastic Small Round Cell Tumor of the Peritoneal Cavity in a 31-Year-Old Male
James Cusack, MD

Poster Presentations

1. Quality of Life after Isolated Limb Perfusion for In-Transit Metastases of Malignant Melanoma. Roger Olofsson Bogge, MD, et. al.
2. Correlation of Morbidity, PCI and Survival, after HIPEC. Horacio Lopez-Basave, MD, et. al.
5. Peritoneal Metastases Observed in Follow-Up After Robotic Cancer Resections May be Distributed by Gravitational Forces. Paul H. Sugarbaker, MD, et. al.
6. HIPEC for Epithelial Ovarian Cancers: Is There a Role? Michelle Boisen, MD, et. al.
8. Isolated Limb Infusion in a Pregnant Patient with Sarcoma of the Upper Limb: Case Report. Vladimir Milovanov, MD, et. al.
11. Serum Cytokine Levels after Isolated Limb Infusion and Ipilimumab in the Treatment of Malignant Melanoma. Jamie Green, MD, et. al.
13. The ASPSM Multi-Institution Evaluation of Laparoscopic Cytoreductive Surgery and HIPEC. Jesus Esquivel, MD, et. al.


20. Neoadjuvant Chemotherapy with Bevacizumab Does Not Affect Complications in Patients with Peritoneal Carcinomatosis From Colorectal Cancer Treated by Cytoreduction and HIPEC. Wenceslao Vasquez-Jimenez, MD, et. al.


22. Routine Admission to ICU After Cytoreductive Surgery (CRS) and HIPEC: Not Always a Requirement. Chukwuemeka Obiora, MD, et. al.

23. Outcomes and Histopathologic Correlation According to Age in Patients with Appendiceal Neoplasms After Cytoreductive Surgery with HIPEC. Maria Fernanda Nunez, MD, et. al.


27. Isolated Chemotherapeutic Perfusion as Neoadjuvant Therapy for Advanced/Unresectable Pelvic Malignancy. Harold Vanebo, MD.

**Course Co-Directors**

H. Richard Alexander, MD  
Professor of Surgery  
University of Maryland School of Medicine  
Baltimore, MD

David L. Bartlett, MD  
Professor of Surgery  
University of Pittsburgh School of Medicine

Robert P. Edwards, MD  
Professor, Obstetrics, Gynecology and Reproductive Sciences  
University of Pittsburgh School of Medicine

T. Clark Gamblin, MD, MS  
Stuart D. Wilson Chair in Surgical Oncology  
Chief, Division of Surgical Oncology  
Associate Professor of Surgery  
Medical College of Wisconsin  
Milwaukee, WI

**Invited Faculty**

Steven Ahrendt, MD  
Associate Professor of Surgery  
University of Pittsburgh School of Medicine

Ronald Alvarez, MD  
Professor, Division of Gynecologic Oncology  
University of Alabama at Birmingham  
Birmingham, AL

Glen Balch, MD  
Assistant Professor of Surgery  
University of Texas Southwestern Medical Center  
Dallas, TX

Lana Bijelic, MD  
Medstar Washington Hospital Center  
Washington, DC

Haroon Choudry, MD  
Assistant Professor of Surgery  
University of Pittsburgh School of Medicine

James Cusack, MD  
Associate Professor of Surgery  
Harvard Medical School  
Boston, MA

Marcello Deraco, MD  
Surgical Oncologist  
Foundation IRCCS Istituto Nazionale dei Tumori  
Milan, Italy

Jesus Esquivel, MD  
Medical Direction, International Oncology Initiatives  
CTCA  
Philadelphia, PA

Jason Foster, MD  
Associate Professor of Surgery  
Nebraska Medical Center  
Omaha, NE

Andrea Hayes-Jordan, MD  
Assistant Professor of Pediatric Surgery  
University of Texas MD Anderson Cancer Center  
Houston, TX

Mary Hesdorffer, NP  
Executive Director  
Mesothelioma Applied Research Foundation  
Alexandria, VA

Matthew Holtzman, MD  
Associate Professor of Surgery  
University of Pittsburgh School of Medicine

John Kane III, MD  
Associate Professor of Oncology  
Roswell Park Cancer Institute  
Associate Professor of Surgery  
University of Buffalo  
Buffalo, NY

Joseph Kim, MD  
Associate Professor of Surgery  
City of Hope National Medical Center  
Duarte, CA
All individuals in a position to control the content of this education activity are required to disclose all relevant financial relationships with any proprietary entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients.

Faculty reside in the Pittsburgh, Pennsylvania, metropolitan area unless indicated otherwise.
Chukwuemeka Ihemelandu, MD  
MedStar Washington Hospital Center  
Washington, DC

Thejus Jayakrishnan, MD  
Medical College of Wisconsin  
Milwaukee, WI

Sean Judge, MD  
Creighton University School of Medicine  
Omaha, NE

Howard Kaufman, MD  
Rutgers Cancer Institute of New Jersey  
New Brunswick, NJ

Minhyung Kim, MD  
Roswell Park Cancer Institute  
Buffalo, NY

Mio Kitano, MD  
The Hospital State University  
Columbus, OH

Shigeki Kusamura, MD  
Milan Tumor Institute  
Milan, Italy

Maryann Kwa, MD  
New York University Cancer Institute  
New York, NY

Rebecca Marmor, MD  
Moores Cancer Center  
San Diego, CA

Vladimir Milovanov, MD  
Mercy Medical Center  
Baltimore, MD

John Miura, MD  
Medical College of Wisconsin  
Milwaukee, WI

Chukwuemeka Obiora, MD  
Wake Forest Baptist Medical Center  
Winston-Salem, NC

Maria Fernanda Nunez, MD  
Mercy Medical Center  
Baltimore, MD

Harveshp Mogal, MD  
Wake Forest School of Medicine  
Winston-Salem, NC

James Paduvis, MD  
University of Pittsburgh School of Medicine  
Pittsburgh, PA

Madalyn Peters, MD  
Hospital of the University of Pennsylvania  
Philadelphia, PA

Patricio Polanco, MD  
UT Southwestern  
Dallas, TX

Michal Radomski, MD  
University of Pittsburgh School of Medicine  
Pittsburgh, PA

Omar Rashid, MD  
H. Lee Moffitt Cancer Center  
Tampa, FL

George Salti, MD  
Edward Hospital Cancer Center/  
University of Illinois at Chicago  
Naperville, IL

Paolo Sammartino, MD  
Sapienza University of Rome  
Rome, Italy

Amod Sarnaik, MD  
H. Lee Moffitt Cancer Center  
Tampa, FL

Richard Sleightholm, MD  
Nebraska Medical Center  
Omaha, NE

Jeffrey Sussman, MD  
University of Cincinnati  
Cincinnati, OH

Alessandro Testori, MD  
Chairman of Melanoma Group  
Milan, Italy

Masahito Tsutsui, MD  
Duke University  
Durham, NC

Rebecca Tuttle, MD  
Roswell Park Cancer Institute  
Buffalo, NY

Daniel Tuvin, MD  
Mount Sinai Medical Center  
New York, NY

Wenceslao Vasquez-Jimenez, MD  
Hospital General Universitario Gregorio Maranon  
Madrid, Spain

Roger Vertrees, PhD  
Verthermia, Inc.  
Burnet, TX (San Jose, CA?)

Harold Wanebo, MD  
Landmark Medical Center  
Woonsocket, RI

Duncan Watley, MD  
Nebraska Medical Center  
Omaha, NE

Yutaka Yonemura, MD  
Kishiwada Tokushukai Hospital  
Osaka, Japan
**Meeting Location**

The conference will be held at the Sheraton Sand Key Resort. Conference reservations are at the sole responsibility of the attendees who may contact the hotel. If registering for a room at the hotel online, please go to [http://www.regionaltherapies.com](http://www.regionaltherapies.com) and click on conference information.

If you wish to make your reservation by phone, please call 1-727-595-1611 and refer to code UPMC15.

The cut-off date for reserving a room at the discounted rate of $205 per night is January 15, 2015.

**Accommodations**

Nightly Guest Room Rate: **$205** per night

*Note: Resorts room rates are subject to additional taxes and resort fees as applicable.*

**Transportation**

For up-to-date transportation information, go to the Koch Center Website: [http://www.regionaltherapies.com](http://www.regionaltherapies.com)

If you are flying to the conference, the closest airport to the Sheraton is the Tampa International Airport.

**For additional information, contact:**

Maureen Hewko, MBA
Telephone: (412) 623-5993
Fax: (412) 692-2520
Email: [hewkom@upmc.edu](mailto:hewkom@upmc.edu)

Koch Center Website: [http://www.regionaltherapies.com](http://www.regionaltherapies.com)

**Visit the Center for Continuing Education in the Health Sciences Web Site**

Our Internet address is: [https://ccehs.upmc.com](https://ccehs.upmc.com)

The UPMC Center for Continuing Education in the Health Sciences invites you to visit our web location. Receive information on CME programs, earn CME credits on the Internet, and access information about our formal courses and much more. Discover who we are and how you can contact us. Please visit our web location often to get updated information on upcoming programs.

---

**Registration Information**

Online Registration is accepted until **February 13, 2015**. After this date, you are only able to register for the conference on site.

Registering online is the quickest and easiest way to reserve your space at CCEHS conferences.

Visit our online registration site at [https://ccehs.upmc.com](https://ccehs.upmc.com). Scroll down to the *Tenth International Symposium on Regional Cancer Therapies* section on the web page.

- Click the registration button and enter all of the requested information.
- After registering, an electronic confirmation will be sent to the email address you provided when you registered.

Registration is not complete until you receive the confirmation email for your preregistration. If you do not receive this letter within 5-7 days of registration, please contact Maureen Hewko at (412) 623-5993.

*You must bring this confirmation with you to the conference.*

**Registration Cancellation**

All cancellations must be in writing and sent to us via US mail, email or fax. Tuition cancellations postmarked or date stamped before **January 15, 2015** will be completely refunded. After **January 15, 2015**, a $35 administrative fee will be assessed. No refunds will be made after **February 1, 2015**.

Conference contact for cancellation requests:

Maureen Hewko, MBA
UPMC Cancer Pavilion 413, 5150 Centre Avenue
Pittsburgh, PA 15232
Email: [hewkom@upmc.edu](mailto:hewkom@upmc.edu) • Telephone: (412) 623-5993
Fax: (412) 692-2520

**Registration Fees**

- **$300** Physicians and researchers
- **$200** Nurses and other health care professionals

Registration fee includes:

- Continuing education credit
- Registration and course materials
- Continental breakfast, refreshments and a light lunch